Better molecules by design

Our innovative pipeline focuses on the development of a diverse array of next-generation therapies predicated on our 40 years of R&D work.

Each of these therapeutic modalities has shown incredible potential, with unique advantages in terms of treatment scenarios, bringing forth new options for powerful drugs that have previously been limited by toxicity concerns.

Product Candidates Therapeutic Index Research Development Pre-Clinical
  IM35-3 Immuno Oncology
   
  Adenosine Receptors A1|A2|A2a|A3
   
  IN21-3 Inflammation
   
  Multiple Targets
   
  CA 85-3 Cancer
   
  Multiple Targets
   
  DE 12-3 Depression
   
  Vasopressin & Serotonin Receptors
   
  CH 31-3 Chronic Pain
   
  Purinergic Receptor P2Y 1-6
   
  AN 4-3 Antipsychotics
   
  Dopamine D1 Receptor
   
  ANT 4 -2 Anticonvulsants
   
  Galanin Receptor 3
   
  ME 7-3 Metastasis
   
  Interleukin-8
   
  AL 2-2 Allergy
   
  Uracil Nucleotide/ Cysteinyl Leukotriene Receptor
   
  DI 16-2 Diabetic
   
  Muscarinic Acetylcholine Receptor M1-5